Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/37751
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | |
dc.contributor.author | NAKANO, Larissa Akeme | |
dc.contributor.author | CANCADO, Eduardo Luiz Rachid | |
dc.contributor.author | CHAVES, Cleuber Esteves | |
dc.contributor.author | MADEIRA, Maria Cristina Vaz | |
dc.contributor.author | KATAYOSE, Jessica Toshie | |
dc.contributor.author | NABESHIMA, Mariana Akemi | |
dc.contributor.author | FOSSALUZA, Victor | |
dc.contributor.author | UHRIGSHARDT, Gabriela Guimaraes | |
dc.contributor.author | Zheng Liting | |
dc.contributor.author | PINTO, Vanusa Barbosa | |
dc.contributor.author | CARRILHO, Flair Jose | |
dc.contributor.author | ONO, Suzane Kioko | |
dc.date.accessioned | 2020-10-15T14:35:19Z | - |
dc.date.available | 2020-10-15T14:35:19Z | - |
dc.date.issued | 2020 | |
dc.identifier.citation | BMC GASTROENTEROLOGY, v.20, n.1, article ID 253, 8p, 2020 | |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/37751 | - |
dc.description.abstract | BackgroundHealth care costs are growing faster than the rest of the global economy, according to the World Health Organization (WHO). Countries' health expenditures include paying for general medicine, diagnostic procedures, hospitalizations and surgeries, as well as medications and prescribed treatment. Primary biliary cholangitis (PBC) is a rare autoimmune liver disease and the first line available treatment is ursodeoxycholic acid (UDCA), however, direct and indirect treatment costs are expensive. Main aim of this trial was to assess if the therapeutic efficacy of UDCA manufactured by the university hospital is equivalent to that of standard UDCA and treatment cost reduction in patients with PBC.MethodsIt is a prospective, interventional, randomized, and crossover study in patients diagnosed with PBC. UDCA 300mg tablets and capsules were developed and manufactured by the university hospital. Thirty patients under treatment with standard UDCA, in stable doses were randomized in sequence A and B, 15 patients in each arm. The groups were treated for 12weeks and after, the UDCA formulation was changed, following for another 12weeks of continuous therapy (tablets and capsules / capsules and tablets). Laboratory tests were performed at time T0 (beginning of treatment), T1 (at the 12week-therapy, before the crossing-over) and T2 (end of treatment). The evaluation was done by comparing the hepatic parameters ALP, GGT, ALT, AST and total bilirubin, also considering the adverse events. The comparison of costs was based on price of the manufactured UDCA and standard UDCA price of the hospital.ResultsHospital reduced 66.1% the PBC treatment costs using manufactured UDCA. There were no differences in the biochemical parameters between sequence (A and B) and tablets or capsules of UDCA formulations applied in the treatment of PBC.ConclusionsThe study showed that there was no significant difference between manufactured UDCA (capsule and tablet) and standard UDCA. Hospital reduced the PBC treatment costs using the manufactured UDCA by the university hospital.Trial registrationClinicalTrials.gov: NCT03489889 retrospectively registered on January 12th, 2018; Ethics Committee approved the study (ID: 1.790.088) on October 25th, 2016. | eng |
dc.description.sponsorship | Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brazil (CAPES)CAPES [001, 1734244] | |
dc.description.sponsorship | Brazilian Council for Development of Science and Technology (CNPq)National Council for Scientific and Technological Development (CNPq) [PQ 308609/2018-2] | |
dc.language.iso | eng | |
dc.publisher | BMC | eng |
dc.relation.ispartof | BMC Gastroenterology | |
dc.rights | openAccess | eng |
dc.subject | Ursodeoxycholic acid | eng |
dc.subject | Primary biliary cholangitis | eng |
dc.subject | Capsules | eng |
dc.subject | Tablets | eng |
dc.subject | Health care costs | eng |
dc.subject | Hospital | eng |
dc.subject.other | cirrhosis | eng |
dc.title | A randomized crossover trial to assess therapeutic efficacy and cost reduction of acid ursodeoxycholic manufactured by the university hospital for the treatment of primary biliary cholangitis | eng |
dc.type | article | eng |
dc.rights.holder | Copyright BMC | eng |
dc.identifier.doi | 10.1186/s12876-020-01399-5 | |
dc.identifier.pmid | 32758152 | |
dc.subject.wos | Gastroenterology & Hepatology | eng |
dc.type.category | original article | eng |
dc.type.version | publishedVersion | eng |
hcfmusp.author.external | FOSSALUZA, Victor:Univ Sao Paulo, Inst Math & Stat, Sao Paulo, Brazil | |
hcfmusp.author.external | UHRIGSHARDT, Gabriela Guimaraes:Univ Sao Paulo, Inst Math & Stat, Sao Paulo, Brazil | |
hcfmusp.author.external | Zheng Liting:Univ Sao Paulo, Inst Math & Stat, Sao Paulo, Brazil | |
hcfmusp.description.articlenumber | 253 | |
hcfmusp.description.issue | 1 | |
hcfmusp.description.volume | 20 | |
hcfmusp.origem | WOS | |
hcfmusp.origem.id | WOS:000561066500002 | |
hcfmusp.origem.id | 2-s2.0-85089170096 | |
hcfmusp.publisher.city | LONDON | eng |
hcfmusp.publisher.country | ENGLAND | eng |
hcfmusp.relation.reference | Boonstra K, 2012, J HEPATOL, V56, P1181, DOI 10.1016/j.jhep.2011.10.025 | eng |
hcfmusp.relation.reference | Dwan K, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4378 | eng |
hcfmusp.relation.reference | Hirschfield GM, 2017, J HEPATOL, V67, P145, DOI 10.1016/j.jhep.2017.03.022 | eng |
hcfmusp.relation.reference | Hopf C, 2013, CLIN PHARM DRUG DEV, V2, P231, DOI 10.1002/cpdd.24 | eng |
hcfmusp.relation.reference | Jessup RL, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-024385 | eng |
hcfmusp.relation.reference | Kulkarni VS, 2016, ESSENTIAL CHEMISTRY FOR FORMULATORS OF SEMISOLID AND LIQUID DOSAGES, P1, DOI 10.1016/C2013-0-18871-X | eng |
hcfmusp.relation.reference | Lindor KD, 2019, HEPATOLOGY, V69, P394, DOI 10.1002/hep.30145 | eng |
hcfmusp.relation.reference | Marin M L, 2001, Rev Hosp Clin Fac Med Sao Paulo, V56, P41 | eng |
hcfmusp.relation.reference | Nolan SJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159014 | eng |
hcfmusp.relation.reference | Packeiser PB, 2014, INFARMA, V26, P215 | eng |
hcfmusp.relation.reference | Pares A, 2006, GASTROENTEROLOGY, V130, P715, DOI 10.1053/j.gastro.2005.12.029 | eng |
hcfmusp.relation.reference | Piazza C, 2010, EUR MAN MED, P461, DOI 10.1007/978-3-540-68940-9_49 | eng |
hcfmusp.relation.reference | Poupon R, 2018, OVERVIEW TREATMENT P | eng |
hcfmusp.relation.reference | Rodrigues JPO, 2015, URSACOL ACID URSODEO | eng |
hcfmusp.relation.reference | Steven P, 2018, DESIGN ANAL CLIN TRI | eng |
hcfmusp.relation.reference | Wellek S, 2012, DTSCH ARZTEBL INT, V109, P276, DOI 10.3238/arztebl.2012.0276 | eng |
dc.description.index | MEDLINE | eng |
dc.identifier.eissn | 1471-230X | |
hcfmusp.citation.scopus | 4 | - |
hcfmusp.scopus.lastupdate | 2024-04-12 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MGT Artigos e Materiais de Revistas Científicas - HC/ICESP Artigos e Materiais de Revistas Científicas - HC/ICHC Artigos e Materiais de Revistas Científicas - LIM/06 Artigos e Materiais de Revistas Científicas - LIM/07 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_NAKANO_A_randomized_crossover_trial_to_assess_therapeutic_efficacy_2020.PDF.pdf | publishedVersion (English) | 877.14 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.